

Modus Therapeutics to Present New Preclinical Data on Sevuparin in Chronic Kidney Disease at EHA2025

Stockholm, Sweden – May 14, 2025 — Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with significant unmet medical needs, today announces that the company has been selected to present a poster at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The presentation will highlight new preclinical data on the investigational drug sevuparin in a model of chronic kidney disease (CKD).

The abstract, titled *“Improvement of Anemia and Kidney Status by Sevuparin Treatment in a Mouse Model of Chronic Kidney Disease,”* describes results from studies conducted in collaboration with researchers at the University of Brescia led by Professor Maura Poli and senior scientist Michela Asperti. The data show that sevuparin, a low-anticoagulant heparinoid compound, significantly improved anemia and kidney status along with a reduction of known fibrosis and damage markers in the kidney tissue from a CKD mouse model, both as a monotherapy and in combination with erythropoietin (EPO).

Key findings include:

- Reduced gene expression of known markers of kidney fibrosis and damage
- Increased hemoglobin and hematocrit levels following sevuparin treatment along with reduced serum hepcidin levels
- The effects were present with sevuparin monotherapy and in combination with EPO

“These results provide further support for the therapeutic potential of sevuparin in treating anemia in chronic inflammation such as kidney disease and offer new insights into its protective effects on kidney function,” said John Öhd, CEO of Modus Therapeutics. “The data are highly relevant to our ongoing Phase IIa clinical study in CKD-related anemia.”

The poster will be presented during Poster Session 2 on **Saturday, June 14, 2025 (18:30–19:30 CEST)** at the MiCo Convention Center in Milan.

The abstract is available via the EHA2025 Congress platform:

EHA2025 Congress

For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Website: www.skmg.se

About Modus Therapeutics and sevuparin

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments

[Modus Therapeutics to Present New Preclinical Data on Sevuparin in Chronic Kidney Disease at EHA2025](#)